Holen Sie sich die Stockscreener-App
94.75
2.56%
2.44
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm CEO to speak at Bank of America healthcare conference May 13 - Stock Titan
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference - GlobeNewswire
Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch By Investing.com - Investing.com Australia
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday - Yahoo Finance
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Rhythm Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) grows Q1 2026 revenue but posts larger net loss - Stock Titan
Rhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth Potential - Yahoo Finance
Rhythm Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Does EU IMCIVREE Expansion for Hypothalamic Obesity Change The Bull Case For Rhythm (RYTM)? - Sahm
Stifel raises Rhythm Pharmaceuticals stock price target on launch - Investing.com UK
Stifel raises Rhythm Pharmaceuticals stock price target on launch By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch - Investing.com
Rhythm Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call - Benzinga
Earnings call transcript: Rhythm Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates - ChartMill
Rhythm Pharmaceuticals (Nasdaq: RYTM) grows IMCIVREE sales and expands approvals - Stock Titan
Rhythm Pharmaceuticals Q1 revenue rises 84% - TradingView
Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q1 Revenue $60.1M, Vs. FactSet Est of $55.8M - Moomoo
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
After FDA approval, rare-obesity drug draws 150 start forms in 6 weeks - Stock Titan
How The Rhythm Pharmaceuticals (RYTM) Narrative Is Shifting On EMANATE Results And IMCIVREE Expansion - Yahoo Finance
Rhythm Pharmaceuticals Q1 2026 earnings preview - MSN
Rhythm Pharmaceuticals (RYTM) Shares New Insights on Pediatric O - GuruFocus
Rhythm Pharmaceuticals earnings in focus after obesity drug wins By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals earnings in focus after obesity drug wins - Investing.com UK
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society - The Manila Times
Rare obesity trial: 44% of treated children reached healthy or overweight - Stock Titan
Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society - TradingView
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105 - Moomoo
MSN Money - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Rhythm Pharmaceuticals Gains on European Approval for Obesity Drug By Investing.com - Investing.com Canada
European Commission approves Imcivree for hypothalamic obesity - Investing.com
European Commission approves Imcivree for hypothalamic obesity By Investing.com - Investing.com India
Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Jennison Associates LLC - MarketBeat
Rhythm Pharmaceuticals Receives EC Authorization for First FDA-Approved Treatment of Acquired Hypothalamic Obesity in Europe - Quiver Quantitative
Europe authorizes first drug for patients with relentless hunger - Stock Titan
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity - ChartMill
MSN - MSN
RYTM Stock Price, Quote & Chart | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
Vanguard Capital Management (RYTM) files Schedule 13G for 5.02% stake - Stock Titan
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Price Weakness - Sahm
[ARS] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Board elections and Say-on-Pay on deck for Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN
Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Analysts estimate Rhythm Pharmaceuticals, Inc. (RYTM) to report a decline in earnings: What to look out for - MSN
Rhythm Pharmaceuticals (RYTM) to Release Earnings on Tuesday - MarketBeat
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Rhythm Pharma wins EU backing to expand Imcivree label - MSN
Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook Reveals 60% Potential Upside In Biotech Sector - DirectorsTalk Interviews
Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Is RYTM a Good Stock to Buy? Bearish Thesis on Rhythm Pharmaceuticals - HarianBasis.co
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):